Keros Therapeutics Inc reports results for the quarter ended March 31 - Earnings Summary

• Keros Therapeutics Inc KROS.OQ reported quarterly adjusted earnings of $3.62​​ per share for the quarter ended March 31, higher than the same quarter last year, when the company reported EPS of $-1.21. The mean expectation of twelve analysts for the quarter was for a loss of 24 cents per share. Wall Street expected results to range from $-1.35 to $3.60 per share.

• Revenue rose 254,413.3% to $211.25 million from a year ago; analysts expected $2.18 million.

• Keros Therapeutics Inc's reported EPS for the quarter was $3.62​.

• The company reported quarterly net income of $148.45 million.

• Keros Therapeutics Inc shares had risen by 42.8% this quarter and lost 8.1% so far this year.

FORECAST CHANGES

• The mean earnings estimate of analysts had risen by about 59.1% in the last three months.​

• In the last 30 days, there have been no earnings estimate revisions by analysts covering the company.

RECOMMENDATIONS

• The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 8 "strong buy" or "buy," 5 "hold" and no "sell" or "strong sell." The average consensus recommendation for the biotechnology & medical research peer group is also "buy"

• Wall Street's median 12-month price target for Keros Therapeutics Inc is $26.00

This summary was machine generated from LSEG data May 6 at 09:05 p.m. UTC. ​All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)